top of page

Empowering Clinicians. Supporting Patients.

GeneFirst are a molecular diagnostics company focused on infectious diseases, cancer diagnostics and personalised medicine. We offer robust, easy-to-use and sensitive molecular diagnostics solutions to researchers, clinicians and drug companies to enable accurate diagnosis and delivery of safe and effective medicines.

GeneFirst are dedicated to empowering healthcare professionals with unique technical innovations designed to overcome limitations of traditional testing solutions.

With a commitment to excellence and a focus on supporting patient outcomes, we strive to be your trusted partner in clinical decision-making.

Explore our portfolio below:

dna-1015661_edited_edited.jpg

Oncology
NGS

3_edited_edited.jpg

Women's Health

1_edited_edited_edited.jpg

Oncology qPCR

4_edited_edited.jpg

Respiratory Infections

Oncology - NGS Library Preparation

Our products specifically address hurdles with processing challenging clinical samples.

Cell-free DNA

Assays designed to maximise the capture of all cell-free DNA, ensuring even the lowest frequency mutation is found.

Targeted cfDNA Enrichment

Total cfDNA Capture

FFPE DNA

Assays designed to capture FFPE DNA, allowing even the lowest quality samples to be successfully processed.

FFPE RNA

Assays designed to capture FFPE RNA and enrich conserved fusion partners to detect and identify every fusion.

ATOM-Seq

Learn more about ATOM-Seq, our novel reimagining of how to process limited or poor-quality clinical samples that achieves the highest quality and sensitivity to provide ultimate confidence in test results.

Oncology - qPCR

High-throughput, single-target mutation detection assays.

JAK2

Mutation Test Kit enables detection of V617F mutation in jak2 gene.

ABL

Mutation Detection Kit enables detection of T315I mutation in ABL gene.

MMD

Using specially designed mutation-specific primers to amplify only DNA that contains targeted mutations. This allows very high sensitivity, making MMD-PCR technology particularly suited for detecting cancerous mutations at very low frequencies.

Women's Health

 To support HPV screening and cervical cancer detection programs, GeneFirst has developed unique HPV-DNA and HPV-RNA solutions based on a novel 
high-throughput multiplexing qPCR technology known as MPA.

HR-HPV DNA

Simultaneous detection and differentiation of all high-risk HPV types including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.

HR-HPV mRNA 

Designed to complement the HR-HPV DNA kit by detecting E6/E7 mRNA to identify risk of cervical cancer in HPV positive individuals 

MPA

Overcomes the limitation of real-time PCR multiplexing by allowing differentiation of up to six different targets per fluorescence channel through the use of differential high-resolution melt curve analysis.

Respiratory Infections

 To support detection of pathogens infecting the upper and lower airways which are responsible for diseases including pneumonia, GeneFirst has developed solutions based on a unique, high-throughput multiplexing qPCR technology (MPA).

Lower Airway

An accurate and sensitive multiplex PCR test for the detection of 9 pathogens associated with community-acquired pneumonia

Upper Airway

An accurate and sensitive multiplex PCR test for the detection of 11 pathogens commonly found in the upper respiratory tract

News and Resources

GeneFirst announces the publication of new health economic evidence...

Harnessing the Potential of Genomics: Empowering Cancer Care through Inherited Mutations and Equitable Access to Genomic Testing

Unleashing the Power of Genome Sequencing in Drug Discovery: Innovative Approaches to 'Drug the Undruggable'

bottom of page